MedTrace Logo

Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers

NCT04516382 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-09-16

No results posted yet for this study

Summary

To estimate the bioavailability of PTG-300 following subcutaneous and intramuscular administration in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

PTG-300

Active drug

Sponsors & Collaborators

  • Protagonist Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director · Protagonist Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-14
Primary Completion
2021-01-12
Completion
2021-06-30
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04516382 on ClinicalTrials.gov